Terumo Corporation (TSE:4543) signed an agreement in principle to acquire Angio-Seal and Femoseal vascular closure products from St. Jude Medical Inc. (NYSE:STJ) in cash on October 18, 2016. Terumo Corporation (TSE:4543) agreed to acquire Angio-Seal and Femoseal vascular closure products on December 7, 2016. In a related transaction, Terumo Corporation signed an agreement to acquire Vado Steerable Sheath business from Abbott Laboratories. Under the terms of the transaction, Terumo will pay $1.12 billion in cash as combined consideration for both Angio-Seal and Femoseal vascular closure products from St. Jude Medical and Vado Steerable Sheath business from Abbott Laboratories. The purpose of the transaction is to obtain certain regulatory approvals in the U.S. and certain foreign jurisdictions that are conditions precedent to completion of the merger of Terumo and St. Jude Medical. The transaction is subject to the successful completion of Abbott’s acquisition of St. Jude Medical, regulatory approval and antitrust approvals. Frank Aquila, Keiji Hatano, Scott Crofton, Steven Holley, Juan Rodriguez, Ronald Creamer Jr, Heather Coleman and Laura Kabler Oswell of Sullivan & Cromwell LLP (Japan) acted as legal advisors to Terumo Corporation. Evercore acted as financial advisor to St. Jude Medical Inc. Terumo Corporation (TSE:4543) completed the acquisition of Angio-Seal and Femoseal vascular closure products from St. Jude Medical, Inc. on January 20, 2017.